AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23827100 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (PSL)
Number of subjects: 138
Study 23827100 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (HDD)
Number of subjects: 138
Study 23827100 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 138
Study 21963360 — intervention group
Group type: COMPARATOR
Intervention: Normal night's sleep
Number of subjects: 39
Study 21963360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction to 5h
Number of subjects: 39
Study 19768922 — intervention group
Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 1780
Study 19768922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1780
Study 15691867 — intervention group
Group type: EXPERIMENTAL
Intervention: l-NAME (180 µg.kg(‐1).h(‐1))
Number of subjects: 8
Study 15691867 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 8
Study 12162933 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of cholesterol absorption, acyl coenzyme A‐cholesterol acyltransferase, microsomal triglyceride transfer protein, cholesteryl ester transfer protein, liver X receptor agonists
Number of subjects: 0
Study 10764243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (more than 550 cigarette-years of exposure)
Number of subjects: 5488
Study 10764243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (more than 300 cigarette-years of exposure)
Number of subjects: 5488
Study 10764243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (all smokers combined)
Number of subjects: 5488
Study 10764243 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (time since last use)
Number of subjects: 5488
Study 7726492 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg every 12 h for five doses)
Number of subjects: 32
Study 7726492 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (250 mg every 6 h for nine doses)
Number of subjects: 32
Study 2406324 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT protocol without preventive measures (290 patients)
Number of subjects: 1152
Study 2406324 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT protocol with pretreatment (160 patients)
Number of subjects: 1152
Study 2406324 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT protocol with pretreatment and preventive measures (479 patients)
Number of subjects: 1152
Study 2406324 — intervention group
Group type: EXPERIMENTAL
Intervention: Step protocol with pretreatment and preventive measures (223 patients)
Number of subjects: 1152
Study 7262184 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1 and 5 micrograms/kg)
Number of subjects: 6
Study 7262184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7262184 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free conditions
Number of subjects: 6
Study 31150072 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game with guns
Number of subjects: 220
Study 31150072 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video game with swords
Number of subjects: 220
Study 31150072 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent video game
Number of subjects: 220
Study 31150072 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent video games (general)
Number of subjects: 220
Study 31150072 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported exposure to violent media
Number of subjects: 220
Study 31150072 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait aggression
Number of subjects: 220
Study 31150072 — intervention group
Group type: EXPERIMENTAL
Intervention: Firearm safety training course
Number of subjects: 220
Study 28283676 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine HCMV‐DNA tests (n=197)
Number of subjects: 243
Study 28283676 — intervention group
Group type: COMPARATOR
Intervention: Blood HCMV‐DNA tests (n=46)
Number of subjects: 243
Study 28283676 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CMV‐specific IgM testing
Number of subjects: 243
Study 28283676 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CMV‐specific IgG testing
Number of subjects: 243
Study 28283676 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous blood and urine HCMV‐DNA tests (n=10)
Number of subjects: 243
Study 28283676 — intervention group
Group type: COMPARATOR
Intervention: Urine HCMV‐DNA tests in parturients (n=25)
Number of subjects: 243
Study 26576124 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 50
Study 26576124 — intervention group
Group type: COMPARATOR
Intervention: Ethanol ablation (EA)
Number of subjects: 50
Study 23795312 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Release Niacin (ERN) titrated from 500mg/night to 1500mg/night
Number of subjects: 17
Study 23795312 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 17
Study 21087857 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (biennial PSA screening)
Number of subjects: 20
Study 21087857 — intervention group
Group type: COMPARATOR
Intervention: Control group (not invited to screening)
Number of subjects: 20
Study 19854593 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term aerobic training (10 sessions of submaximal aerobic cycling, 35 min for each session, 3 times a week)
Number of subjects: 20
Study 19854593 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term aerobic training
Number of subjects: 20
Study 19854593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 17100739 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacalcitol cream with 308-nm monochromatic excimer light (MEL) therapy
Number of subjects: 38
Study 17100739 — intervention group
Group type: COMPARATOR
Intervention: Vehicle with 308-nm monochromatic excimer light (MEL) therapy
Number of subjects: 38
Study 16224678 — intervention group
Group type: EXPERIMENTAL
Intervention: NexGen LPS Flex mobile knee prosthesis
Number of subjects: 60
Study 16224678 — intervention group
Group type: COMPARATOR
Intervention: NexGen LPS
Number of subjects: 60
Study 12385678 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX/CA 2000/125 mg bid
Number of subjects: 5531
Study 12385678 — intervention group
Group type: COMPARATOR
Intervention: Comparators (levofloxacin 500 mg od, clarithromycin 500 mg bid, AMX/CA 875/125 mg bid and tid, AMX/CA 1000/125 mg tid)
Number of subjects: 5531
Study 12385678 — intervention group
Group type: COMPARATOR
Intervention: Comparators (for PRSP)
Number of subjects: 5531
Study 10385761 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (2 intravenous bolus injections of 10 U 30 minutes apart)
Number of subjects: 36
Study 10385761 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (intravenous infusion of a total dose of 100 mg over a 2‐hour period, including an initial 10‐mg bolus)
Number of subjects: 36
Study 10385761 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 36
Study 10385761 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 36
Study 10385761 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase and Alteplase
Number of subjects: 36
Study 8789581 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hours of passive recovery between exercise sessions (3 on 1)
Number of subjects: 9
Study 8789581 — intervention group
Group type: COMPARATOR
Intervention: Approximately 24 hours of recovery between exercise sessions (3 con)
Number of subjects: 9
Study 8789581 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarisation trials
Number of subjects: 9
Study 2174446 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg per day for 3 weeks
Number of subjects: 82
Study 2174446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 7004471 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 63
Study 31958480 — intervention group
Group type: EXPERIMENTAL
Intervention: Food distractors
Number of subjects: 51
Study 31958480 — intervention group
Group type: COMPARATOR
Intervention: Toy distractors
Number of subjects: 51
Study 30882135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (alcohol screening and brief advice)
Number of subjects: 229
Study 30882135 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation
Number of subjects: 229
Study 28439109 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib–lenalidomide–dexamethasone (ASPIRE)
Number of subjects: 984
Study 28439109 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib–dexamethasone (ENDEAVOR)
Number of subjects: 984
Study 26105170 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily (arm 1)
Number of subjects: 37
Study 26105170 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg twice daily initially then 400 mg twice daily after 4 weeks (arm 2)
Number of subjects: 37
Study 24315882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (5 μg oral, once daily for 12 weeks)
Number of subjects: 296
Study 24315882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 12 weeks)
Number of subjects: 296
Study 24315882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron
Number of subjects: 296
Study 21627752 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal slit method
Number of subjects: 5142
Study 21627752 — intervention group
Group type: COMPARATOR
Intervention: Sleeve method
Number of subjects: 5142
Study 21627752 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cautery
Number of subjects: 5142
Study 19250979 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes communication system using mobile phones and patient/physician portals
Number of subjects: 260
Study 19250979 — intervention group
Group type: COMPARATOR
Intervention: Usual care from primary care physicians (PCPs)
Number of subjects: 260
Study 17559787 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Chamber Intraocular Lens (PC IOL)
Number of subjects: 1102
Study 17559787 — intervention group
Group type: COMPARATOR
Intervention: Anterior Chamber Intraocular Lens (AC IOL)
Number of subjects: 1102
Study 17559787 — intervention group
Group type: COMPARATOR
Intervention: Insufficient Capsular Support (ICS)
Number of subjects: 1102
Study 17559787 — intervention group
Group type: COMPARATOR
Intervention: Nonvitreous Presentation (NVP)
Number of subjects: 1102
Study 15608392 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP‐E regimen (cyclophosphamide 750 mg/m², epirubicin 50 mg/m², vincristine 2 mg, etoposide 80 mg/m² on day 1 and oral prednisone 100 mg on days 1 to 5)
Number of subjects: 51
Study 15608392 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOP‐E regimen
Number of subjects: 51
Study 12000411 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health intervention (hospital and home visits, telephone support for 6 months)
Number of subjects: 41
Study 12000411 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study 12000411 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health intervention
Number of subjects: 41
Study 9846858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (60 mL)
Number of subjects: 8
Study 9846858 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestible fat
Number of subjects: 8
Study 9846858 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 8
Study 8081594 — intervention group
Group type: EXPERIMENTAL
Intervention: Actiferrin Compositum (1 capsule per day from 36th week, increasing to 2 capsules per day until childbirth)
Number of subjects: 84
Study 8081594 — intervention group
Group type: COMPARATOR
Intervention: Control group (57 non-anaemic not treated pregnant women)
Number of subjects: 84
Study 8081594 — intervention group
Group type: EXPERIMENTAL
Intervention: Actiferrin Compositum
Number of subjects: 84
Study 2682862 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho‐Vaxom (BV)
Number of subjects: 104
Study 2682862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 4609544 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 94
Study 4609544 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics
Number of subjects: 94
Study 31994716 — intervention group
Group type: EXPERIMENTAL
Intervention: Givosiran (subcutaneously administered)
Number of subjects: 0
Study 31994716 — intervention group
Group type: EXPERIMENTAL
Intervention: Givosiran (once monthly dosing)
Number of subjects: 0
Study 31994716 — intervention group
Group type: COMPARATOR
Intervention: Givosiran (once quarterly dosing)
Number of subjects: 0
Study 29396658 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 488
Study 26779911 — intervention group
Group type: COMPARATOR
Intervention: US‐CNPB
Number of subjects: 150
Study 26779911 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐ANPB
Number of subjects: 150
Study 24886238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-moderated group-based internet intervention
Number of subjects: 819
Study 24886238 — intervention group
Group type: EXPERIMENTAL
Intervention: Single clinic-based appointment plus nurse-moderated group-based internet intervention
Number of subjects: 819
Study 24886238 — intervention group
Group type: COMPARATOR
Intervention: Single home-visit with subsequent standard services
Number of subjects: 819
Study 22268662 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter training
Number of subjects: 22
Study 22268662 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched patients)
Number of subjects: 22
Study 20306535 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic capsules (656 mg daily)
Number of subjects: 34
Study 20306535 — intervention group
Group type: COMPARATOR
Intervention: Olive oil capsules (656 mg daily) - Control
Number of subjects: 34
Study 18361977 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural vision enhancement technology (NVC, NeuroVision, Inc.)
Number of subjects: 20
Study 16197584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water 2
Number of subjects: 18
Study 16197584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral water 1
Number of subjects: 18
Study 16197584 — intervention group
Group type: COMPARATOR
Intervention: Low mineral water
Number of subjects: 18
Study 16197584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonated mineral waters (1 and 2)
Number of subjects: 18
Study 16197584 — intervention group
Group type: EXPERIMENTAL
Intervention: All water types
Number of subjects: 18
Study 12182215 — intervention group
Group type: EXPERIMENTAL
Intervention: DEF
Number of subjects: 17
Study 12182215 — intervention group
Group type: EXPERIMENTAL
Intervention: ADQ
Number of subjects: 17
Study 10598763 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-mode ruby laser treatment
Number of subjects: 17
Study 10598763 — intervention group
Group type: COMPARATOR
Intervention: Shaved test area (control)
Number of subjects: 17
Study 7795836 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol/d)
Number of subjects: 353
Study 7795836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 2309177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (2 g) plus cloxacillin (2 g) as a single-dose infusion after division of the cord
Number of subjects: 0
Study 2309177 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin (2 g)
Number of subjects: 0
Study 6169424 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation schedule of 2000 rad in one week
Number of subjects: 1830
Study 6169424 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation schedule of 4000 rad in four weeks
Number of subjects: 1830
Study 30582271 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine 80/5 mg
Number of subjects: 150
Study 30582271 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS 30 mg
Number of subjects: 150
Study 29962098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial internal rotation (IR) group performing leg press activity with tibia in maximal IR
Number of subjects: 60
Study 29962098 — intervention group
Group type: COMPARATOR
Intervention: Neutral rotation (NR) group performing leg press activity with tibia in neutral rotation
Number of subjects: 60
Study 27072821 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin-secreting papillary renal cell carcinoma (PRCCM) tumors
Number of subjects: 7
Study 24975713 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic nephrectomy
Number of subjects: 62
Study 24975713 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneoscopic nephrectomy
Number of subjects: 62
Study 22017815 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI breakfast
Number of subjects: 52
Study 22017815 — intervention group
Group type: COMPARATOR
Intervention: High-GI breakfast
Number of subjects: 52
Study 20978060 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (interactive booklet and DVD)
Number of subjects: 572
Study 20978060 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard information for Australian national bowel screening programme)
Number of subjects: 572
Study 18471658 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 946
Study 18471658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized studies
Number of subjects: 946
Study 18471658 — intervention group
Group type: EXPERIMENTAL
Intervention: Case reports
Number of subjects: 946
Study 16154016 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg adding perindopril 4-8 mg as required
Number of subjects: 19257
Study 11849191 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ARTS (120 mg)
Number of subjects: 12
Study 11849191 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. ARTS (120 mg)
Number of subjects: 12
Study 11849191 — intervention group
Group type: EXPERIMENTAL
Intervention: rectal DHA (160 mg)
Number of subjects: 12
Study 11084179 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Number of subjects: 50
Study 11084179 — intervention group
Group type: COMPARATOR
Intervention: Copper T380A intrauterine device
Number of subjects: 50
Study 9188111 — intervention group
Group type: EXPERIMENTAL
Intervention: Self made introducer for LMA placement
Number of subjects: 251
Study 1416875 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin (7.5 mg/kg) with piperacillin (4 g every 12 h for four doses)
Number of subjects: 12
Study 1416875 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (2 mg/kg) with piperacillin (4 g every 12 h for four doses)
Number of subjects: 12
Study 1416875 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin alone
Number of subjects: 12
Study 2991817 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (synthetic ACTH 4-9 analog), administered for 6 months
Number of subjects: 77
Study 2991817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 31163232 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensionally printed MMS model with standardized education (SE)
Number of subjects: 82
Study 31163232 — intervention group
Group type: COMPARATOR
Intervention: Standardized education (SE) alone
Number of subjects: 82
Study 29054507 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based teaching tool
Number of subjects: 40
Study 29054507 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic teaching
Number of subjects: 40
Study 26414912 — intervention group
Group type: EXPERIMENTAL
Intervention: one tablet weekly (one/week)
Number of subjects: 49
Study 26414912 — intervention group
Group type: EXPERIMENTAL
Intervention: one tablet twice weekly (two/week)
Number of subjects: 49
Study 26414912 — intervention group
Group type: EXPERIMENTAL
Intervention: two tablets twice weekly (four/week)
Number of subjects: 49
Study 26414912 — intervention group
Group type: EXPERIMENTAL
Intervention: one tablet daily (seven/week)
Number of subjects: 49
Study 26414912 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥4/week regimens
Number of subjects: 49
Study 26414912 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 49
Study 26414912 — intervention group
Group type: EXPERIMENTAL
Intervention: All analytes in serum and PBMCs
Number of subjects: 49
Study 26414912 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-state daily dosing serum TFV and PBMC TFV-DP
Number of subjects: 49
Study 25363219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 2403 mg/day
Number of subjects: 178
Study 25363219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (from CAPACITY study)
Number of subjects: 178
Study 25363219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (from CAPACITY study)
Number of subjects: 178
Study 25363219 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 178
Study 23584329 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (ballistic bench throws 1x3 repetitions at 30% 1-RM bench press)
Number of subjects: 36
Study 23584329 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (8 minutes of rest)
Number of subjects: 36
Study 20940646 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (manual massage and compression)
Number of subjects: 32
Study 20940646 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression treatment
Number of subjects: 32
Study 20940646 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 32
Study 18936064 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral steroids before planned extubation
Number of subjects: 1923
Study 18936064 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose regimen of steroids
Number of subjects: 1923
Study 18936064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1923
Study 16638415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept 15 mg administered subcutaneously (SC)
Number of subjects: 50
Study 16638415 — intervention group
Group type: COMPARATOR
Intervention: Alefacept 15 mg administered intramuscularly (IM)
Number of subjects: 50
Study 16638415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept SC
Number of subjects: 50